Business
GMT: Genomtec's Q1 2025 loss widened as R&D ramped up, with commercialization still pending
GMT: Genomtec's Q1 2025 loss widened as R&D ramped up, with commercialization still pending
About this update from Genomtec Sa
Genomtec S.A. reported increased R&D spending and a wider net loss in Q1 2025, with no significant product sales but strengthened cash position after a capital raise. Key projects remain in development, with future growth dependent on commercialization and external funding.Original document: This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.